Dr. Scott Rocklage is a managing partner at 5AM Ventures. He started out as a venture partner at the firm in 2003. He was promoted to managing partner a year later. 5AM Ventures is a venture capital firm that invests in companies in the life-sciences industry. They invest in early stage rounds.
This is where the name of the equity firm was found. He has been able to discover three drugs that were approved by the Food and Drug Administration over the course of his career.
The drugs include Teslascan, Omniscan, and Cubicin. Dr. Rocklage studied at the University of California, Berkeley and graduated with a degree in Chemistry. He went on to join MIT where he earned his Ph.D. in Chemistry. Rocklage conducted his research in Richard Schrock’s lab.
Scott Rocklage is a distinguished researcher. He has written hundreds of peer-reviewed papers. It is also important to note that he holds several patents for his role in the invention of novel technologies.
Scott Rocklage has gained a lot of management experience over the years. He gained the experience from the different positions that he has served. He started his career in the Research and Development departments of Catalytic and Salutar. He served as the chief executive officer and the chairman of Cubist Pharmaceuticals for several years. He acted as the CEO and president of Nycomed Interventional Inc. from 1990 to 1994.
Rocklage is the chairman of the boards of several healthcare companies including Semprus, Cidara, and Achaogen. He was the executive chairman of two enterprises that were known as Miikana and Ilypsa.
He is also a member of the board of Pulmatrix, WaveRx, Rennovia, and the Whitehead Institute. He was appointed the Director of Relypsa Inc. in August 2007.
He held this role for seven years. He acted as the director of Cubist Pharmaceuticals and Protana Inc. for a period of ten years. He was appointed the CEO of Epirus Biopharmaceuticals last year. He maintained the position for a short time. Dr. Scott Rocklage also acted as the director of the company.